| Danish Elder Lymphoma Patient Hematopoietic Investigation (NCT05245487) | Rigshospitalet, Denmark | 2022-01-01 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab (NCT04887831) | G1 Therapeutics, Inc. | 2021-06-04 |
| Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma (NCT04460508) | The First Hospital of Jilin University | 2020-12-20 |
| Study to Evaluate the Usability of PointCheck (NCT04448314) | Leuko Labs, Inc. | 2020-02-11 |
| Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (NCT03294577) | BeyondSpring Pharmaceuticals Inc. | 2019-10-23 |
| Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer (NCT04101760) | Lei Li | 2019-10-01 |
| Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia (NCT03846414) | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 2019-02-13 |
| Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients (NCT03823950) | University of Mississippi Medical Center | 2019-02-01 |
| G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients (NCT03793205) | Lei Li | 2019-01-03 |
| Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis (NCT03701841) | Anhui Provincial Hospital | 2018-10-01 |
| Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (NCT03102606) | BeyondSpring Pharmaceuticals Inc. | 2018-05-29 |
| Plinabulin iv Solution in Prevention of TAC Induced Neutropenia (NCT04227990) | BeyondSpring Pharmaceuticals Inc. | 2017-11-27 |
| Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients (NCT03251768) | Tianjin SinoBiotech Ltd. | 2017-10-19 |
| Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia (NCT03559387) | Prolong Pharmaceuticals | 2017-08-03 |
| Community-Led Action Research in Oncology: Improving Symptom Management (NCT03208816) | Dartmouth-Hitchcock Medical Center | 2017-07-24 |
| Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 (NCT04345900) | BeyondSpring Pharmaceuticals Inc. | 2017-04-05 |
| Pegteograstim in Children With Solid Tumors (NCT02787876) | Samsung Medical Center | 2016-10-04 |
| Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN (NCT04460079) | Cinnagen | 2016-03-29 |
| Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum (NCT05512676) | Oslo University Hospital | 2016-03-07 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer (NCT02725606) | Jiangsu T-Mab Biopharma Co.,Ltd | 2016-03-01 |
| Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (NCT02692742) | Myelo Therapeutics GmbH | 2016-03-01 |
| Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients (NCT03246009) | Tianjin SinoBiotech Ltd. | 2016-01-21 |
| Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects (NCT02643901) | Jiangsu T-Mab Biopharma Co.,Ltd | 2015-09-01 |
| Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers (NCT02700360) | Enzychem Lifesciences Corporation | 2015-08-01 |
| A Safety and PK Study of EC-18 in Healthy Subjects (NCT02496143) | Enzychem Lifesciences Corporation | 2015-07-01 |
| Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers (NCT02532712) | Enzychem Lifesciences Corporation | 2015-03-01 |
| Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein (NCT02465801) | Tianjin SinoBiotech Ltd. | 2014-12-16 |
| Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study (NCT02454530) | Pfizer | 2014-09-01 |
| Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer (NCT02251977) | Yuhong Li | 2014-09-01 |
| Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients (NCT02104830) | Biocad | 2013-09-01 |
| Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors (NCT02156388) | Jiangsu T-Mab Biopharma Co.,Ltd | 2013-08-01 |
| Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (NCT01735175) | Sandoz | 2012-06-01 |
| Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer (NCT01569087) | Biocad | 2012-05-01 |
| Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (NCT01516736) | Sandoz | 2012-03-01 |
| Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia (NCT01674855) | Dong-A ST Co., Ltd. | 2012-02-01 |
| GCPGC in Chemotherapy-induced Neutropenia (NCT01328938) | Green Cross Corporation | 2010-10-01 |
| Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia (NCT01923545) | Dong-A ST Co., Ltd. | 2010-07-01 |
| Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (NCT01126190) | Teva Branded Pharmaceutical Products R&D, Inc. | 2010-06-30 |
| Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (NCT00837265) | Teva Branded Pharmaceutical Products R&D, Inc. | 2008-08-21 |
| Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF) (NCT00776165) | Shantha Biotechnics Limited | 2007-10-01 |
| Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy (NCT00501332) | Maxygen Holdings Ltd. | 2007-07-01 |